Intended for healthcare professionals
Management

Topical keratolytics in psoriasis management

Julie Van Onselen

RGN, RSCN, DipM, DipN, BA(Hons), Derm Cert, Teaching Cert Lecturer Practitioner, Dermatology Education Partnership Ltd and Stirling University

Psoriasis is common skin condition with symptoms of dry, flaking and scaly skin. Theses symptoms should be managed with keratolytics, which will prevent dry skin and reduce scaling. Keratoytics should be a first-line therapy in managing psoriasis, as scale needs to be removed to ensure topical treatment efficacy. This article reviews the use of topical kaeratolytics in psoriasis management.

Dermatology in practice 2019; 25(1): 24–26
To continue reading this article, please sign in or register.

Dermatology in practice was previously supported by Wyeth from 2008 to 2010, by Wyeth and Serono in 2007, by Wyeth and Shire from 2005 to 2006, by Medlock Medical in 2004 and by SSL International from 2001 to 2003.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the publisher, Editor or Editorial Board. Accordingly the publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Dermatology in practice is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2021 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to:

ISSN 0262-5504 (Print) ISSN 2049-8446 (Online)